Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

Rakesh Popat, Jamie Cavenagh, Louise Flanagan et al.|The Lancet Haematology|2016

Cited by 43